---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-263543"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:41:03.435190+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies: TSHA-102 gets FDA Breakthrough Therapy, Q3 net loss $32.7M

## Summary
- FDA granted Breakthrough Therapy designation for TSHA-102 in Rett syndrome; FDA alignment finalized on REVEAL pivotal trial protocol with 6-month interim analysis to expedite BLA.
- First patient dosing in REVEAL pivotal trial scheduled Q4 2025; enrollment to continue at multiple sites.
- Regained full unencumbered rights to TSHA-102 after Astellas option agreement expired in October 2025.
- Q3 2025 net loss $32.7M ($0.09/share); R&D $25.7M; cash $297.3M expected to fund operations into 2028.
- David McNinch appointed Chief Commercial Officer in September 2025; TSHA-102 generally well tolerated with no treatment-related SAEs in 12 patients.

## SEC filing metadata
- accession: 0001193125-25-263543
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312525263543/0001193125-25-263543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312525263543/d17004d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-263543
- JSON: https://secwatch.observer/filing/0001193125-25-263543.json
- Plain text: https://secwatch.observer/filing/0001193125-25-263543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.